Regeneron stock holds near a 52-week high after a strong quarter.

Regeneron Pharmaceuticals Inc. (ISIN US75886F1075) stock closed at $805.93 on August 17, 2026, just below its 52-week high of $821.11 and above the $629.68 post-trial low from May 18, 2026. The move comes after July 30, 2026 earnings showed $14.29 in quarterly EPS on $4.29 billion in revenue.

Earnings still set the tone

The latest quarter mattered because it beat the $10.16 EPS consensus by $4.13 and topped revenue expectations of $3.82 billion by $470 million. Revenue rose 16.7 percent from the same quarter a year earlier, while prior-year EPS was $12.81, showing that growth is still reaching both the top and bottom line.

That combination helps explain why the shares are holding close to the top of the 52-week range even after a year with sharp swings. The stock's close on August 17, 2026 also sat well above the 50-day moving average of $679.69 and the 200-day moving average of $714.24.

Dividend and ownership

Regeneron also declared a quarterly dividend of $0.94 per share, payable on August 31, 2026, with an annualized rate of $3.76 and a yield of 0.5 percent at recent trading levels. BlackRock disclosed 9,113,506 shares valued at $5.68 billion, or an 8.62 percent stake, in a filing summary published on August 18, 2026.

That mix of profit growth and cash return gives the stock a different profile from the post-earnings-only trade many biotech names still rely on. Analysts compiled in recent market coverage still show a Moderate Buy consensus with an average target near $801.70, which leaves the current price slightly above the average view.

Eylea remains central

Eylea remains the clearest product reference point inside the portfolio, because it anchors the ophthalmology franchise and remains tied to major commercial and legal developments. Recent market coverage also pointed to a settlement tied to an Eylea biosimilar candidate, reinforcing that the eye-care business remains both commercially important and legally active.

For Regeneron, the key question is no longer whether the company can generate profit. The bigger question is whether $4.29 billion quarterly revenue and a 27.86 percent net margin can keep supporting a stock that is already close to its 52-week peak.

Regeneron shares today

As of August 17, 2026, Regeneron stock stood at $805.93 on Nasdaq with a market value of $83.03 billion. The gap to the 52-week high is $15.18, while the rebound from the May 18, 2026 low is $176.25.

More on Regeneron shares

Regeneron Pharmaceuticals Inc. uses its biologics platform across ophthalmology, immunology and oncology, with Eylea as the best-known commercial product. The company’s recent results show how that product mix still translates into earnings power.

Fact box

Company: Regeneron Pharmaceuticals Inc.
ISIN: US75886F1075
Ticker: REGN
Exchange: Nasdaq
Price (as of August 17, 2026, 4:00 p.m. ET): $805.93 USD
Market cap: $83.03 billion (as of August 17, 2026)
Sector / Industry: Health care / Biotechnology
Index membership: S&P 500